EPIDIOLEX® (cannabidiol): A New Treatment Option for Seizures Associated with Tuberous Sclerosis Complex (TSC)
Epidiolex® (cannabidiol): A New Treatment Option for Seizures Associated with Tuberous Sclerosis Complex (TSC)
Sponsored by Greenwich Biosciences, Inc.
Wednesday, September 2, 2020, 2-3pm ET
Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in TSC1 or TSC2 genes and affects approximately 50,000 people in the United States. TSC causes benign tumors to form in many different organs, and up to 90% of individuals with TSC have refractory epilepsy and nearly two-thirds are pharmacoresistant.
EPIDIOLEX® (cannabidiol) is the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) and is approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients 1 year of age and older.
The FDA approved EPIDIOLEX for a third indication for seizures associated with TSC in patients 1 year of age and older on July 31, 2020.
This webinar will provide an overview of the disease burden of TSC and review the clinical trial data for EPIDIOLEX for the treatment of seizures in this syndrome.
- Kelly Hollenack, PharmD, MBA, MS
Director, Health Outcomes Liaisons
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
** IMPORTANT: AMCP webinars are limited to the first 1000 that join the webinar. The recording and slides of sponsored webinars will be provided if permitted by the sponsor.
For individuals from the media/press who are interested in attending, please email firstname.lastname@example.org.